公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2017 | mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib | Meyer T.; Palmer D.H.; ANN-LII CHENG ; Hocke J.; Loemb? A.-B.; Yen C.-J. | Liver International | 59 | 49 | |
2013 | Neuropilin-2 contributes to tumorigenicity in a mouse model of Hedgehog pathway medulloblastoma | Hayden Gephart M.G.; Su Y.S.; Bandara S.; FENG-CHIAO TSAI ; Hong J.; Conley N.; Rayburn H.; Milenkovic L.; Meyer T.; Scott M.P. | Journal of Neuro-Oncology | 21 | 16 | |
2014 | A polarized Ca2+, diacylglycerol and STIM1 signalling system regulates directed cell migration | FENG-CHIAO TSAI ; Seki A.; Yang H.W.; Hayer A.; Carrasco S.; Malmersjö S.; Meyer T. | Nature Cell Biology | 178 | 169 | |
2020 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial | Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG ; Meyer T.; Abou-Alfa G.K. | ESMO open | 47 | 46 | |
2020 | Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma | Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG ; El-Khoueiry A.B.; Abou-Alfa G.K. | Clinical Cancer Research | 54 | 44 | |
2013 | XThe proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit | Spencer S.L.; Cappell S.D.; FENG-CHIAO TSAI ; Overton K.W.; Wang C.L.; Meyer T. | Cell | 435 | 417 |